N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-morpholin-4-ylethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide | 1182745-65-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-morpholin-4-ylethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
• 英文别名: N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-[2-(morpholin-4-yl)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide；N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-(2-morpholin-4-ylpropan-2-yl)-6-oxopyrimidine-4-carboxamide
• CAS: 1182745-65-8
• 化学式: C₂₀H₂₅FN₄O₄
• 分子量: 404.441
• InChiKey: LVSLGGSSHFNPJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  94.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  吗啉 、 2-(1-dimethylamino-1-methylethyl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide trifluoroacetate 以 N-甲基吡咯烷酮 为溶剂， 反应 48.0h， 生成 N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-morpholin-4-ylethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
  参考文献：
  名称：

  Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

  摘要：

  Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl-4-hydroxypyrimidinone-carboxamides, which exhibited potent inhibition of the HIV-integrase catalyzed strand transfer process. Structural modifications on these molecules were made in order to maximize potency as HIV-integrase inhibitors against the wild type virus, a selection of mutants, and optimize the selectivity, pharmacokinetic, and metabolic profiles in preclinical species. The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection.

  DOI：

  10.1021/jm800245z